Head and neck for Viralytics
Tuesday, 09 December, 2008
Sydney biotech Viralytics has been authorised to start a trial of its Cavatak oncolytic virus technology in head and neck cancers.
The company is running Phase I trials of the technology in late stage melanoma, prostate and breast cancers.
The new trial will involve nine patients with recurrent, inoperable tumours of the head and neck.
Cavatak is a coxsackievirus-based formulation which attaches itself to receptors on the cell surface that are highly expressed in some solid tumours.
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
